What Wound Care Audits Are Actually Testing
There is a belief circulating in wound care that has become genuinely dangerous: that if a provider builds a solid documentation template — wound size, chronicity, conservative care failure, ABI, smoking cessation, all the expected fields — they are protected. That belief is wrong.
Claims are being denied where the documentation is complete. Appeals are being denied where the clinical rationale is sound. The same patient, the same date of service, the same record — audited more than once, with different outcomes each time. The American Professional Wound Care Association described the current environment in a 2025 statement as one "many providers now describe as existential," noting practices forced to close before the appeals process could be exhausted. [1] That is not a documentation problem. That is a systemic enforcement posture, and understanding what it is actually testing is the starting point.
None of this means practices cannot survive it. Providers who understand what the scrutiny actually requires are navigating it. That starts with knowing what changed — and what it now takes to build a defensible record.
The Documentation Standard Has Shifted — Not Just the Rules
The change in documentation requirements is not simply a matter of new LCD criteria replacing old ones. What has shifted is the fundamental standard of what "good documentation" means.
For years, meeting the LCD meant hitting the required data points: wound measurements, conservative care timeline, chronicity evidence, ABI. If those elements were present, the claim was covered. That logic still governs how billing review works. It does not govern how audit review works.
What auditors are now evaluating is not whether the documentation checked the boxes — it is whether the record tells a coherent, patient-specific clinical story. Why this patient. Why this wound. Why this product, at this point in the treatment course. A templated note that satisfies every field on a checklist is not the same as a narrative that could withstand line-by-line scrutiny from a federal contractor.
The harder truth is that even a well-constructed narrative may not prevent a denial. The documented case of a clinician who prevailed at the Administrative Law Judge level — after three consecutive denials from a UPIC and MAC — required a 40-page ALJ ruling to reach resolution, 14 months of proceedings, and specialized legal support throughout. [2] The standard that wins at the ALJ level is different from the standard that avoids an initial denial. Providers need to understand that distinction before a demand letter arrives, not after. For a full breakdown of the five appeal levels and what each one requires, see our companion piece on the audit landscape.
Staying current matters as much as starting right. The documentation requirements governing skin substitute claims have changed multiple times in recent years and will continue to evolve. Practices that build documentation processes around the requirements of a prior cycle — and don't actively track what the current LCD and billing articles require — are generating records that may clear billing review today and fail audit review later. Keeping up with the standard as it moves is part of what defensible practice now looks like. [3]
The UPIC Audit Isn't Just Reviewing Your Chart
Most providers who have thought about audit exposure have thought about it in clinical terms: was the wound documented, was conservative care established, was medical necessity supported by the record. That is one standard. It is not the only one being applied.
A UPIC audit demand circulated in wound care compliance circles in 2025 ran to 39 line items. Alongside the standard medical record requirements, the demand included all invoices for skin substitutes and wound care products over the prior 12 months, all order forms, any rebate agreements with distributors or manufacturers, and marketing materials presented to the practice by industry. [4]
The auditor is not reviewing the claim in isolation. They are reviewing the commercial structure around the claim. That means distributor agreements, group purchasing organization contracts, rebate arrangements, consignment deals, and any marketing or financial arrangement between the practice and a manufacturer or distributor. UPIC contractors can refer cases directly to OIG's Office of Investigations. [4] That is a different kind of exposure than most practices have prepared for.
The DOJ's June 2025 national healthcare fraud takedown — the largest in the department's history, charging 324 defendants in connection with over $14.6 billion in alleged fraud — identified skin substitutes as a named priority and specifically cited illegal kickbacks from graft distributors to providers as a driving mechanism. [5] Rebate agreements and marketing arrangements are not automatically problematic, but they are now explicitly on the checklist of a federal audit contractor with a referral path to the agency that just ran the largest healthcare fraud enforcement action on record.
Providers who have not reviewed those relationships in that context should.
What January 2026 Changed at the Practice Level
The policy restructuring that took effect January 1, 2026 added a separate layer to an already difficult environment. CMS reclassified most skin substitutes from biologic-equivalent products to incident-to medical supplies under the Physician Fee Schedule, establishing a flat national reimbursement rate of $127.14 per square centimeter regardless of product. [6]
The reimbursement change created a practical problem around product sizing that has not been clearly addressed. Manufacturers developed their product size lines — 2x2, 2x3, 3x3, 4x4, 4x6 and so on — within a biologics framework that accounted for wastage. Incident-to reimbursement does not. A provider treating a wound that requires a specific coverage area will often need to use the next available size up to meet the clinical requirements described in the product's IFU or supporting literature. The reimbursement will be paid on the full product size. The audit exposure comes later.
Medicare has no mechanism to flag the mismatch at the point of payment — the claim goes through. But history has demonstrated that when auditors review those claims on the back end, a product applied to a wound area smaller than the product size used creates vulnerability, particularly if the documentation does not support a clinical rationale for the size selected. The fixation edge argument — the idea that overlap serves a clinical function that justifies the size differential — is being explored as a documented basis for that rationale, but at this point it has not been established with supporting data in a way that has been validated through the audit process. [7] No one has been audited under the incident-to model yet. The full consequences are still speculative. But the pattern from prior audit cycles suggests CMS will revisit these claims, and no practice wants to be the first to find out.
What the Practices that Get Through This Have in Common
Providers navigating this environment are not doing it by avoiding audits. They are doing it by being defensible when audits arrive.
Their records are built to meet the standard that matters — not billing clearance, but audit survival. That means patient-specific clinical narratives, not template-filled fields. It means documentation that explains the clinical reasoning behind each treatment decision in language that can hold up under line-by-line review by a federal contractor. Noridian's published documentation requirements for skin substitute claims provide a useful baseline: the record should support the diagnosis codes billed, document the product utilized, account for wastage, and include prior treatment notes — but that is the floor, not the ceiling. [3]
Their product selection rationale is in the record. Whatever drove the selection of a specific product for a specific patient — clinical indication, wound characteristics, prior response, product properties — that reasoning needs to be documented before the claim is filed. The issue is not how the product was selected. The issue is whether the selection can be explained and supported in the record if it is ever questioned.
Their vendor arrangements can withstand scrutiny. That means knowing what agreements exist — distributor contracts, rebate structures, GPO terms, any arrangement that involves pricing, compensation, or product access — and being able to produce and explain them in response to a UPIC demand that will explicitly ask for all of it.
Tools that support more defensible documentation exist. OpenEvidence is a clinical decision support platform some wound care providers have used to build more rigorous clinical records — not a guarantee against denial, but one input into a process that now requires deliberate construction. [8]
Most practices that were billing skin substitutes prior to 2026 will face some level of review. The enforcement pipeline does not stop because the reimbursement model changed. The question is whether the record and the commercial structure around it can hold up when the review arrives — and whether the practice has stayed current enough with evolving requirements to know what holding up actually requires.
The providers who are getting through this understand what they are actually operating in. That is where it starts. If you’re not sure exactly where you stand and want to talk through it, reach out.
**References**
[1] Sykstus, B.M. "When Compliance Is Not Enough: Skin Substitute Audits, Due Process, and the Limits of Federal Oversight." American Professional Wound Care Association, 2025. https://www.apwca.org/news/13593553
[2] Fife, C. "Here Comes the Judge! Part 2 of the Incredible Journey of a Skin Substitute Audit." Guest Blog by Michael Crouch. CarolineFifeMD.com, November 2025. https://carolinefifemd.com/2025/11/17/skin-substitute-audit-part-2/
[3] Noridian Medicare. "Skin Substitute and Wound Care Documentation Requirements." https://med.noridianmedicare.com/web/jeb/topics/documentation-requirements/skin-substitute-wound-care
[4] Kelso, M. "UPIC Auditors Demand Skin Substitute Invoices & Rebate Agreements." Guest Blog, CarolineFifeMD.com, March 2025. https://carolinefifemd.com/2025/03/18/skin-substitute-invoices/
[5] U.S. Department of Justice. "National Health Care Fraud Takedown Results in 324 Defendants Charged in Connection with Over $14.6 Billion in Alleged Fraud." June 30, 2025. https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-324-defendants-charged-connection-over-146
[6] WoundReference. "2026 CMS Rules for Skin Substitutes: Billing, Payment & Coverage FAQ." https://woundreference.com/p/blog?id=skin-substitutes---whats-new-in-2026-frequently-asked-questions
[7] Frier Levitt. "Frier Levitt's Success at an ALJ Hearing Highlights the Importance of Understanding Medicare Wound Care Audits." https://www.frierlevitt.com/articles/frier-levitts-success-at-an-alj-hearing-highlights-the-importance-of-understanding-medicare-wound-care-audits/
[8] OpenEvidence. https://www.openevidence.com